Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163345
Status:
COMPLETED
Last Update Posted:
2016-12-08
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma 18 to 60 y BY9010M1-131
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Evaluation of Parameters of the Small Airways and Their Changes Under Treatment With Ciclesonide 320 mcg Once Daily Versus Placebo in Patients With Asthma
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the involvement of small airways in asthma as determined by bronchial challenges CT-scanning and cellular markers of inflammation Ciclesonide will be inhaled at one dose level once daily The study duration consists of a baseline period 2 to 3 weeks and a treatment period 5 to 6 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None